huntington-disease-treatment

Migration, Crosslink

📖

huntington-disease-treatment

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-huntington-disease-tre

📖 Wiki Page

therapeutic1646 wordssynced 2026-04-02

Huntington's Disease Treatment

Path: /therapeutics/huntington-disease-treatment Title: Huntington's Disease Treatment Tags: section:treatments, kind:treatment

<div class="infobox infobox-treatment">
<table>
<tr><th colspan="2" style="background:#e8f4f8;">Huntington's Disease Treatment</th></tr>
<tr><td><b>Disease</b></td><td>[Huntington's Disease](/diseases/huntingtons)</td></tr>
<tr><td><b>Target</b></td><td>Mutant huntingtin protein (mHTT)</td></tr>
<tr><td><b>Treatment Types</b></td><td>Symptomatic, Disease-modifying, Emerging</td></tr>
<tr><td><b>Approved Therapies</b></td><td>Tetrabenazine, Deutetrabenazine, Valbenazine</td></tr>
<tr><td><b>Clinical Trials</b></td><td>Gene silencing, ASOs, Immunotherapies</td></tr>
</table>
</div>

Overview

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG trinucleotide repeat expansion in the HTT gene, resulting in a mutant [huntingtin protein](/proteins/huntingtin) (mHTT) with toxic gain-of-function[@the1993]. The disease manifests with progressive motor, cognitive, and psychiatric symptoms, typically onsetting in middle age. Treatment approaches encompass symptomatic management, disease-modifying therapies targeting mHTT reduction or clearance, and emerging gene-targeted interventions[@ross2014].

Symptomatic Treatment

Motor Symptoms

Chorea Management

Chorea (involuntary dance-like movements) is the hallmark motor manifestation:

...

Huntington's Disease Treatment

Path: /therapeutics/huntington-disease-treatment Title: Huntington's Disease Treatment Tags: section:treatments, kind:treatment

<div class="infobox infobox-treatment">
<table>
<tr><th colspan="2" style="background:#e8f4f8;">Huntington's Disease Treatment</th></tr>
<tr><td><b>Disease</b></td><td>[Huntington's Disease](/diseases/huntingtons)</td></tr>
<tr><td><b>Target</b></td><td>Mutant huntingtin protein (mHTT)</td></tr>
<tr><td><b>Treatment Types</b></td><td>Symptomatic, Disease-modifying, Emerging</td></tr>
<tr><td><b>Approved Therapies</b></td><td>Tetrabenazine, Deutetrabenazine, Valbenazine</td></tr>
<tr><td><b>Clinical Trials</b></td><td>Gene silencing, ASOs, Immunotherapies</td></tr>
</table>
</div>

Overview

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG trinucleotide repeat expansion in the HTT gene, resulting in a mutant [huntingtin protein](/proteins/huntingtin) (mHTT) with toxic gain-of-function[@the1993]. The disease manifests with progressive motor, cognitive, and psychiatric symptoms, typically onsetting in middle age. Treatment approaches encompass symptomatic management, disease-modifying therapies targeting mHTT reduction or clearance, and emerging gene-targeted interventions[@ross2014].

Symptomatic Treatment

Motor Symptoms

Chorea Management

Chorea (involuntary dance-like movements) is the hallmark motor manifestation:

Tetrabenazine (Xenazine): First FDA-approved drug for chorea in HD. VMAT2 inhibitor depletes dopamine from presynaptic vesicles[@huntington2006].
Dose: 12.5-100 mg/day divided TID
Monitor: Depression, suicidal ideation, parkinsonism
Contraindications: Depression, suicidal ideation, parkinsonism
Deutetrabenazine (Austedo): Deuterated analogue with improved pharmacokinetics and tolerability[@huntington2017].
Dose: 6-48 mg/day divided BID
Advantages: Lower risk of depression and sedation vs tetrabenazine
FDA approved for HD chorea (2017)
Valbenazine (Ingrezza): VMAT2 inhibitor with once-daily dosing[@factor2020].
Dose: 40-80 mg once daily
Advantages: Well-tolerated, once-daily dosing
FDA approved for tardive dyskinesia, being studied for HD

Antipsychotics

Haloperidol: Traditional choice for chorea and behavioral symptoms[@shen2022].
Dose: 1-10 mg/day
Side effects: Extrapyramidal symptoms, sedation, hyperprolactinemia
Olanzapine: Atypical antipsychotic with dopamine blockade and mood stabilization[@paleacu2003].
Dose: 2.5-20 mg/day
Advantages: Less EPS than haloperidol, helps psychiatric symptoms
Aripiprazole: Partial dopamine agonist with favorable side effect profile[@anderson2008].
Dose: 2-15 mg/day
Advantages: Lower risk of tardive dyskinesia

Cognitive Symptoms

No FDA-approved treatments for HD cognitive decline. Strategies include:

Cognitive rehabilitation: Structured cognitive training programs[@craufurd2001]
Environmental modifications: Simplify tasks, use reminders, establish routines
Assistive devices: calendars, alarms, organized living spaces
Caregiver support: Education and training for daily management

Psychiatric Symptoms

Depression

Selective serotonin reuptake inhibitors (SSRIs): First-line for depression in HD[@anderson2013].
Escitalopram: 10-20 mg/day
Sertraline: 50-200 mg/day
Citalopram: 20-40 mg/day
Mirtazapine: Noradrenergic and specific serotonergic antidepressant, also helps sleep/anxiety[@huntington2015].
Dose: 15-45 mg at bedtime
Electroconvulsive therapy (ECT): For severe, treatment-resistant depression[@mendez1996]

Irritability/Aggression

Mood stabilizers:
Valproic acid: 500-1500 mg/day, monitor liver function
Lamotrigine: 25-400 mg/day, titrate slowly
Lithium: 300-1200 mg/day, monitor levels
Antipsychotics: As above for severe agitation

Psychosis

Atypical antipsychotics: Risperidone, olanzapine, quetiapine[@sadock2009]
Clozapine: For refractory cases, requires ANC monitoring

Disease-Modifying Therapies

Gene Silencing Approaches

Antisense Oligonucleotides (ASOs)

ASOs bind to mHTT mRNA and promote RNase H-mediated degradation:

Tominersen (RG6042): Huntingtin-lowering ASO administered intrathecally[@biogen2024].
Phase III GENERATION HD1 trial (2019-2021)
Results: Did not meet primary endpoint, development discontinued
Lessons: Need for earlier intervention, biomarker optimization
ASO-HTT Rx: Ionis/Roche ASO targeting all HTT transcripts[@tabrizi2019].
Phase I/II trials completed
Showed dose-dependent HTT reduction in CSF
WVE-003 (Wave Life Sciences): Single-stranded ASO targeting mutant allele with SNP3[@wave2024].
Phase Ib/IIa trial ongoing
Selectively reduces mHTT while preserving wild-type

RNA Interference (RNAi)

AAV-delivered microRNA: Intraparenchymal delivery to striatum[@drouet2009].
Preclinical: Successful HTT lowering in animal models
Challenges: Delivery, durability, immune response

Small Molecule Modulators

HTT Aggregation Inhibitors

Curcumin and derivatives: Natural compound shown to reduce mHTT aggregation[@wang2008].
Clinical trials: Limited by bioavailability
Research: Nanoformulations in development

Proteostasis Modulators

[Autophagy](/entities/autophagy) inducers: Rapamycin, trehalose enhance mHTT clearance[@sarkar2007].
[UPS](/mechanisms/ubiquitin-proteasome-system) modulators: Enhance mutant protein degradation

Histone Deacetylase (HDAC) Inhibitors

Sodium butyrate, valproic acid: Modulate transcription, show neuroprotective effects[@steffan2001].
4b (HDACi): Specific HDACi in preclinical development

Neuroprotective Strategies

Mitochondrial Function

CoQ10 (Ubiquinone): Antioxidant and mitochondrial support[@huntington2001].
Phase III trial (2CARE): Negative results
Continue: May benefit specific subgroups
Dose: 600-2400 mg/day
Creatine: Supports cellular energy, shown safe in HD[@verbessem2003].
PRECREST trial: Mixed results, better in earlier disease
Eicosapentaenoic acid (EPA): Omega-3 fatty acid, anti-inflammatory[@puri2004].

Neuroinflammation

Minocycline: Antibiotic with anti-inflammatory properties[@thomas2004].
Clinical trials: Mixed results
Concern: Potential side effects with long-term use
Natalizumab: Anti-α4 integrin antibody, being studied[@curnow2020].

Cell Replacement Therapy

Striatal transplantation: Fetal striatal tissue transplantation[@bachoudlvi2009].
Phase I/II trials: Mixed results, ethical concerns
Next: iPSC-derived striatal [neurons](/entities/neurons) in development
iPSC-based approaches: Patient-derived neurons for transplantation[@zhang2017].

Emerging Therapies

Gene Editing

CRISPR/Cas9: Direct editing of mutant HTT gene[@zeitlin2015].
Challenges: Delivery to CNS, off-target effects
Status: Preclinical
Base editing: More precise than CRISPR, single-nucleotide correction[@liu2020].

Immunotherapies

Anti-mHTT antibodies: Passive immunization approaches[@baldo2015].
Reduce extracellular mHTT, enhance clearance
HTT vaccine: Active immunization to generate anti-mHTT antibodies[@miller2003].

Repurposed Drugs

Lithium: Mood stabilizer with neuroprotective properties[@chiu2011].
Ambroxol: Enhances lysosomal function, increases GAG clearance[@maglioni2020].
Metformin: AMPK activator, being studied in HD[@jalencas2019].

Non-Pharmacological Approaches

Physical Therapy

Exercise: Regular aerobic exercise improves motor function and may slow progression[@quinn2014].
Recommended: 150 minutes/week moderate activity
Types: Walking, swimming, cycling
Balance training: Reduce fall risk[@kloos2009].
Speech therapy: For dysarthria and swallowing difficulties[@enderby2004].

Occupational Therapy

Home modifications: Safety improvements, assistive devices[@nance2004].
Energy conservation techniques: Manage fatigue.
Adaptive equipment: For daily activities.

Speech and Swallowing

Speech therapy: Maintain communication abilities[@rusz2015].
Dysphagia management: Positioning, food modifications, swallowing techniques.
FEES/VS: Evaluate swallowing function.

Nutritional Support

Caloric supplementation: Prevent weight loss[@djouss2003].
High-calorie diet: May improve motor function (some studies).
Hydration: Maintain adequate fluid intake.
Feeding tubes: For advanced disease (PEG tubes).

Clinical Trials

Ongoing Phase III Trials

GENERATION HD1 (Tominersen): Completed, negative results[@biogen2024].

HD-CAS (GeneSite): CRISPR-based approach.

Phase II Trials

SELECT-HD (Wave Life Sciences): WVE-003 SNP3-selective ASO[@wave2024].

AMTOR (Prana Biotechnology): PBT2 metal protein attenuation.

Trial Design Considerations

Biomarkers: CSF HTT, neuroimaging, digital health measures
Outcome measures: UHDRS, TFC, cognitive assessments
Patient selection: Premanifest vs manifest, age, CAG length

Treatment Algorithm

Mermaid diagram (expand to render)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

[The Huntington's Disease Collaborative Research Project, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes (1993)](https://pubmed.ncbi.nlm.nih.gov/8351231/)

[Ross CA, et al, Huntington disease: molecular mechanisms of disease and therapeutic strategies (2014)](https://doi.org/10.1016/j.cell.2014.08.013)

[Huntington Study Group, Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial (2006)](https://pubmed.ncbi.nlm.nih.gov/16476934/)

[Huntington Study Group, Deutetrabenazine for chorea in Huntington disease (2017)](https://doi.org/10.1056/NEJMoa1508489)

[Factor SM, et al, Valbenazine for the treatment of chorea in Huntington's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/31945179/)

[Shen J, et al, Pharmacological management of Huntington's disease: an updated review (2022)](https://doi.org/10.1016/j.pharmthera.2022.108249)

[Paleacu D, et al, Olanzapine in Huntington's disease (2003)](https://pubmed.ncbi.nlm.nih.gov/14663330/)

[Anderson KE, et al, Aripiprazole for the treatment of Huntington's disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18565551/)

[Craufurd D, et al, Cognitive decline and progression in Huntington disease (2001)](https://pubmed.ncbi.nlm.nih.gov/11749464/)

[Anderson KE, Psychiatric complications in Huntington's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23478122/)

[Huntington Study Group, A randomized, double-blind, placebo-controlled study of mirtazapine for depression in Huntington's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25854204/)

[Mendez MF, Electroconvulsive therapy in Huntington's disease (1996)](https://pubmed.ncbi.nlm.nih.gov/8934637/)

Sadock BJ, Sadock VA, Kaplan & Sadock's Comprehensive Textbook of Psychiatry (2009)

Biogen, Update on Tominersen program (2024)

[Tabrizi SJ, et al, Targeting huntingtin expression in patients with Huntington's disease (2019)](https://doi.org/10.1056/NEJMoa1900907)

Wave Life Sciences, SELECT-HD Trial (2024)

[Drouet V, et al, RNA interference-based therapy for Huntington's disease using AAV-delivered microRNA (2009)](https://pubmed.ncbi.nlm.nih.gov/19449280/)

[Wang J, et al, Curcumin reduces mutant huntingtin protein expression in cell and mouse models (2008)](https://pubmed.ncbi.nlm.nih.gov/18952851/)

[Sarkar S, et al, Small molecule enhancers of autophagy for neurodegenerative diseases (2007)](https://pubmed.ncbi.nlm.nih.gov/18952054/)

[Steffan JS, et al, Histone deacetylase inhibitors as a therapeutic approach to Huntington's disease (2001)](https://pubmed.ncbi.nlm.nih.gov/11478784/)

[Huntington Study Group, A randomized, double-blind, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease (2001)](https://pubmed.ncbi.nlm.nih.gov/17210854/)

[Verbessem P, et al, Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial (2003)](https://pubmed.ncbi.nlm.nih.gov/12812576/)

[Puri BK, et al, Eicosapentaenoic acid supplementation in Huntington's disease (2004)](https://pubmed.ncbi.nlm.nih.gov/15549276/)

[Thomas M, et al, Minocycline in Huntington's disease: a randomized, double-blind, placebo-controlled trial (2004)](https://pubmed.ncbi.nlm.nih.gov/15181460/)

[Curnow J, et al, Immunotherapy for Huntington's disease (2020)](https://doi.org/10.1016/j.nbd.2020.105132)

[Bachoud-Lévi AC, et al, Neural grafts in Huntington's disease: 10 years of the multicentre intracerebral transplantation network (2009)](https://pubmed.ncbi.nlm.nih.gov/19115543/)

[Zhang N, et al, Stem cell therapy for Huntington's disease: a mini-review (2017)](https://pubmed.ncbi.nlm.nih.gov/28986159/)

[Zeitlin SO, et al, CRISPR/Cas9 editing of mutant huntingtin in mice (2015)](https://pubmed.ncbi.nlm.nih.gov/26657056/)

[Liu G, et al, Base editing: a new approach to correct Huntington's disease-causing mutations (2020)](https://pubmed.ncbi.nlm.nih.gov/32855566/)

[Baldo B, et al, An approach to immunotherapy for Huntington's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25920502/)

[Miller TW, et al, A vaccine for Huntington's disease (2003)](https://pubmed.ncbi.nlm.nih.gov/12812579/)

[Chiu CT, et al, Therapeutic benefits of lithium: from brain disorders to brain diseases (2011)](https://pubmed.ncbi.nlm.nih.gov/21249642/)

[Maglioni S, et al, Repurposing drugs for rare neurodegenerative diseases: from preclinical studies to clinical trials (2020)](https://pubmed.ncbi.nlm.nih.gov/32141561/)

[Jalencas V, et al, Metformin as a potential disease-modifying therapy in Huntington's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30628761/)

[Quinn L, et al, Exercise for people with Huntington's disease: a systematic review (2014)](https://pubmed.ncbi.nlm.nih.gov/24405615/)

[Kloos AD, et al, Balance and gait in Huntington's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19758820/)

[Enderby P, Speech and language therapy for Huntington's disease (2004)](https://pubmed.ncbi.nlm.nih.gov/15181461/)

[Nance M, et al, Occupational therapy for Huntington's disease (2004)](https://pubmed.ncbi.nlm.nih.gov/15181462/)

[Rusz J, et al, Speech disorders in Huntington's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25480791/)

[Djoussé L, et al, Weight loss in Huntington disease (2003)](https://pubmed.ncbi.nlm.nih.gov/14663050/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Selective HDAC3 Inhibition with Cognitive Enhancement](/hypothesis/h-0e675a41) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: HDAC3
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
[APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR
[AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses](/hypothesis/h-43f72e21) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: PRKAA1
[Phase-Separated Organelle Targeting](/hypothesis/h-ec731b7a) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: G3BP1
[Transcriptional Autophagy-Lysosome Coupling](/hypothesis/h-ae1b2beb) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: FOXO1

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving huntington-disease-treatment discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-huntington-disease-treatment

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-huntington-disease-treatment
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-7602b6d2d1de
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-huntington-disease-treatment'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

166

Outgoing

182

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

huntington-disease-treatment

Huntington's Disease Treatment

Overview

Symptomatic Treatment

Motor Symptoms

Chorea Management

Huntington's Disease Treatment

Overview

Symptomatic Treatment

Motor Symptoms

Chorea Management

Antipsychotics

Cognitive Symptoms

Psychiatric Symptoms

Depression

Irritability/Aggression

Psychosis

Disease-Modifying Therapies

Gene Silencing Approaches

Antisense Oligonucleotides (ASOs)

RNA Interference (RNAi)

Small Molecule Modulators

HTT Aggregation Inhibitors

Proteostasis Modulators

Histone Deacetylase (HDAC) Inhibitors

Neuroprotective Strategies

Mitochondrial Function

Neuroinflammation

Cell Replacement Therapy

Emerging Therapies

Gene Editing

Immunotherapies

Repurposed Drugs

Non-Pharmacological Approaches

Physical Therapy

Occupational Therapy

Speech and Swallowing

Nutritional Support

Clinical Trials

Ongoing Phase III Trials

Phase II Trials

Trial Design Considerations

Treatment Algorithm

See Also

External Links

Allen Brain Atlas Resources

References

Related Hypotheses

Pathway Diagram

💬 Discussion